Aims Serum C-reactive protein has prognostic significance in apparently healthy men and women and in men with coronary artery disease. Little is known regarding the predictive role of C-reactive protein in women with coronary heart disease. We assessed whether differences exist in C-reactive protein levels and their prognostic value in men compared with women. We also assessed whether C-reactive protein concentrations differed in women receiving hormone replacement therapy vs those on no hormone replacement therapy.
Introduction
Inflammation plays a role in atherogenesis and the development of acute coronary syndromes (i.e. unstable angina and myocardial infarction) [1] . A feature of most forms of inflammation or tissue damage is the increased serum concentration of acute phase reactants such as C-reactive protein, fibrinogen and serum amyloid A protein [2] , and a good correlation has been found among these proteins [3] . Elevated serum C-reactive protein levels have been reported in patients with acute myocardial ischaemia [4] , myocardial infarction [5, 6] and unstable angina [7] and large studies [8] [9] [10] [11] have shown an association between C-reactive protein and risk of coronary heart disease. The findings of these studies [8] [9] [10] [11] , however, largely relate to men; in the MRFIT and PHS studies [9, 10] only apparently healthy men were investigated and in the ECAT study [8, 11] , women, who constituted approximately 14% of the stable angina population, were not analysed separately.
Whether findings in men can be directly extrapolated to women is not known. Gender differences may exist which may be important in the clinical setting. It is of interest that baseline levels of acute phase reactants such as fibrinogen have been reported to differ between men and women even after appropriate adjustment for relevant variables [12] . Little is known regarding the value of C-reactive protein measurements in women with chronic stable angina pectoris and the gender differences that may exist in baseline C-reactive protein levels. Studies in apparently healthy women [13,14,14a] have shown that C-reactive protein is a predictor of cardiovascular risk. Controversial information has been published about the effects of hormone replacement therapy on C-reactive protein levels. It has been recently reported that apparently healthy women using hormone replacement therapy had higher C-reactive protein levels than women not using hormone replacement therapy [15] [16] [17] . However, hormone replacement therapy in diabetic women has been shown to reduce C-reactive protein levels [18] . In the present study in patients with exertional angina pectoris we sought to assess whether gender differences exist in baseline C-reactive protein levels and the prognostic value of C-reactive protein concentration. We also assessed if, in women with coronary artery disease, hormone replacement therapy influences C-reactive protein serum concentration.
Methods
From a population of 1345 consecutive patients with typical exertional chest pain who underwent elective coronary angiography in our centre between November 1994 and April 1997, 924 patients (332 women) were prospectively selected for study. Eligible patients were men and women with chronic stable angina and positive responses to exercise ECG stress testing and/or abnormal myocardial perfusion scintigraphy. Stable angina was defined as typical exertional chest pain relieved by rest and/or GTN administration. In all patients symptoms were stable for at least 3 months before study entry. We did not include patients with the following: unstable angina (crescendo angina, angina at rest or recent (less than 1 month) onset angina), recent (<12 weeks) myocardial infarction, previous coronary angioplasty or coronary bypass surgery, malignant arrhythmias, valve heart disease, acute or chronic liver disease, renal failure, inflammatory diseases or other severe conditions likely to cause death within 1 year. None of the patients included in this study had connective tissue disorders, rheumatic conditions or immune disorders which could have affected C-reactive protein plasma levels. Of the 924 patients initially selected, 13 were excluded from analysis: three men died within 72 h of elective myocardial revascularization, one woman was diagnosed with advanced cancer soon after diagnostic angiography, three women had severe arthritic pains and required treatment with steroids, and six patients (0·7%) were lost for follow-up. Therefore, 911 patients (327 women) constituted the study population and all have been included in the statistical analysis. Patient management, including the decision to proceed to urgent revascularization during follow-up, was left to the discretion of the treating physician.
All patients gave written informed consent before study entry and the local Ethics Committee approved the study. Patients' clinical, biochemical and angiographic characteristics are summarized in Table 1 .
Follow-up and study end-points
After recruitment and baseline characterization, patients were followed at regular intervals. Follow-up ranged from 1·0 year to 3·7 years (median 1·6 years). Major clinical events during follow-up considered to represent study end-points were: (1) hospital admission with Braunwald's class IIIb unstable angina, (primary rest angina within 48 h prior to admission), requiring intravenous treatment and/or coronary revascularization; (2) myocardial infarction, defined according to WHO criteria [19] as elevated cardiac enzymes, characteristic electrocardiographic changes and prolonged typical chest pain; (3) stroke, defined as neurological deficit of sudden or rapid onset that persisted for more than 24 h; and (4) cardiac death.
We aimed to compare baseline C-reactive protein levels and the prognostic role of C-reactive protein measurements in men with stable exertional angina versus women with exertional angina pectoris. As a secondary end-point we assessed differences in Creactive protein levels in women receiving hormone replacement therapy versus those on no hormone replacement therapy.
Study protocol

Clinical characterization
At study entry, the data acquired included age, gender, height, weight, blood pressure, menopausal status and assessment of risk factors including a history of: myocardial infarction, systemic hypertension, diabetes mellitus, smoking, hypercholesterolaemia, a family history of coronary artery disease, stroke and intermittent claudication. Cardiac medications taken at study entry, specifically aspirin, beta-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors, digoxin, diuretics, lipid-lowering drugs, nitrates and hormone replacement therapy were recorded.
Blood sampling and C-reactive protein measurement
Fasting blood samples were obtained from every patient before diagnostic coronary angiography. Blood was drawn and centrifuged immediately. Serum was then aliquoted and stored at 80 C. No specimen inadvertently thawed during storage. C-reactive protein measurements were performed on the COBAS Integra
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(Roche Diagnostics Limited, Lewes, East Sussex, U.K.) using the CRP-Latex assay in both the high sensitivity application (analytical range 0·2-12 mg . l 1 ) and the normal application (analytical range 2-160 mg . l 1 ). Analytical precision of the high sensitivity CRP-Latex assay was 7·6% at a level of 1·02 mg . l 1 , 3·3% at 1·79 mg . l 1 and 1·3% at a level of 4·36 mg . l 1 . Samples outside the analytical range of the high sensitivity CRP-Latex assay were analysed by the CRP-Latex assay in the normal application. The analytical precision of the normal CRP-Latex assay was 2·4% at a level of 29·5 mg . l 1 and 1·3% at a level of 113 mg . l 1 .
Coronary angiography
Coronary angiography was carried out according to the Judkins technique and images of the coronary tree were obtained in routine standardized projections with the digital Philips Integris 3000 system (Philips, Holland). Two experienced cardiologists, unaware of the patients' clinical history and C-reactive protein levels, reviewed all angiographic images. Coronary arteries were considered to have significant stenoses in the presence of d75% lumen diameter narrowing [20] . Patients with stenoses <75% were considered to have '0-vessel disease'.
Statistical analysis
The SPSS 8.0 statistical package (SPSS Inc) was used. Proportions were compared using the chi-squared test. The two-tailed Fisher exact test was used when appropriate. Analysis of normality of the continuous variables was performed with the Kolmogorov-Smirnov test. Student's t-test was used to assess differences between quantitative variables with a normal distribution. The significance of any differences in median values between male and female gender was assessed using the MannWhitney U test. As C-reactive protein serum concentration had a non-normal distribution, C-reactive protein concentrations were logarithm transformed before any regression analysis was performed in order to fulfil the conditions required for multiple regression analysis. The influence of gender on serum C-reactive Date are presented as mean standard deviation, median (interquartile interval) or n (%).
protein concentration was analysed using multiple regression analysis. Logistic regression analysis was carried out to assess the independent prognostic value of C-reactive protein (overall, and separately for men and women). Results are expressed as mean SD for normally distributed variables, median (interquartile interval) for non-normal distributed quantitative variables, and as n (%) for qualitative variables. All P values are two-tailed and confidence intervals (CIs) have been calculated at the 95% level.
Results
Baseline clinical findings
Baseline characteristics in all patients included in the study are shown in Table 1 . Five hundred and eightyfive men aged 62·9 9·5 years and 327 women (35·9% of the total patient population) aged 63·5 9·2 years were studied. Three hundred women in the study were postmenopausal, 63 of whom were receiving hormone replacement therapy (19·3%). The median time of hormone replacement therapy treatment was 3·4 years (interquartile interval, 1·0-6·2 years). Women on hormone replacement therapy with an intact uterus received opposed oestrogen therapy, whereas women without a uterus received unopposed oestrogen therapy. Thirty women were pre-menopausal (9·2%). The median time from onset of menopause was 15 years (interquartile interval, 6·0-22·0 years). Overall, smokers had significantly higher C-reactive protein levels than non-smokers (P=0·002). C-reactive protein levels, however, were not significantly raised in patients with diabetes mellitus, in patients with high plasma cholesterol or in patients with a history of prior myocardial infarction. As assessed by univariate analysis, hypertensive patients (P<0·001) and patients who received diuretics (P<0·001) had higher levels of C-reactive protein even after age and gender adjustment.
C-reactive protein baseline levels were significantly higher in women than in men (P<0·001). Women also had significantly higher plasma cholesterol (6·10 1·31 mmol . l 1 vs 5·84 1·04 mmol . l 1 , P=0·002) and lower triglyceride levels (1·39 [range 1·00-1·93] mmol . l 1 vs 1·60 [range 1·10-2·14] mmol . l 1 , P=0·005) than men. A larger proportion of women than men had a family history of ischaemic heart disease (60·9% vs 50·9%, P=0·003). Conversely, more men than women had had a previous myocardial infarction (38·5% vs 19·6%, P<0·001), and there was also a higher proportion of smokers among men than women (73·3% vs 53·9%, P<0·001). More men than women were receiving treatment with aspirin at study entry (82·7% vs 67·6%, P<0·001). Eighty-four patients (9·2% of the total patient population) had normal coronary arteriograms. Table 2 shows the baseline variables in women with and those without hormone replacement therapy. Univariate analysis showed a tendency for C-reactive protein levels to be higher in women receiving hormone replacement therapy compared with those on no hormone replacement therapy, but this difference was not statistically significant (P=0·060). C-reactive protein levels, however, were significantly higher in both women receiving hormone replacement therapy and those on no hormone replacement therapy when compared with men (both P<0·009).
Baseline serum C-reactive protein and gender: multivariate analysis
After adjustment for risk factors and the significant variables at the univariate analysis, i.e. body mass index, age, hypertension, aspirin, beta-blocker, diuretic, lipidlowering therapy, smoking, number of vessels diseased, history of myocardial infarction, hyperlipidaemia, intermittent claudication and family history, C-reactive protein (CRP) serum concentration remained significantly lower in men than in women (log 10 [CRP], 0·100 [95% CI, 0·161-0·040]; P=0·001) ( Table 3 ). In our series, the independent effect of gender on C-reactive protein levels was of similar magnitude to that of smoking, albeit of opposite sign (0·113 [95% CI, 0·052-0·174]; P<0·0005).
C-reactive protein and hormone replacement therapy in women: multivariate analysis
The independent variables introduced in the model were hormone replacement therapy and those factors that were different at univariate analysis between hormone replacement therapy users and non-users, i.e. age, systolic blood pressure, cholesterol, hypertension, left ventricular ejection fraction and number of vessels diseased, with C-reactive protein as the dependent variable. When adjusted, women not receiving hormone replacement therapy had lower C-reactive protein serum concentrations ( 0·213 [95% CI, 0·333-0·093]; P=0·001) than those using hormone replacement therapy. In our series, the magnitude of the independent effect of hormone replacement therapy on C-reactive protein levels was similar, but of opposite direction, to the independent effect induced by two decades of life (C-reactive protein increase with one decade of life increase: 0·100 [95% CI, 0·051-0·150]; P<0·0005). Table 4 shows quartiles of C-reactive protein for men, women using hormone replacement therapy and women without hormone replacement therapy. Table 5 shows C-reactive protein concentrations in men, women on no hormone replacement therapy and women receiving hormone replacement therapy in relation to
C-reactive protein concentration and extent of coronary artery disease
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the number of coronary vessels diseased. In all three patient subgroups, coronary disease ranged from none to three vessel disease, but women with hormone replacement therapy had significantly less vessel disease and had higher C-reactive protein than women with no hormone replacement therapy. Women on hormone replacement therapy with no vessel disease had higher C-reactive protein serum concentrations than men with . Not in the model: family history (P=0·22), prior myocardial infarction (P=0·30), beta-blocker therapy (P=0·30), aspirin (P=0·32), left ventricular ejection fraction (P=0·33), hypercholesterolaemia (P=0·41), number of vessels diseased (P=0·58), lipid-lowering treatment (P=0·59), intermittent claudication (P=0·60), systolic blood pressure (P=0·92). Men (n=584) c1·00 1·01-2·10 2·11-4·20 d4·21 Women, no HRT (n=264) c1·20 1·21-2·69 2·70-5·40 d5·41 Women using HRT (n=63) c1·80 1·81-3·20 3·21-6·24 d6·25
HRT=hormone replacement therapy.
three-vessel disease (P=0·059), but had a significantly lower event rate (P=0·008). In men, serum C-reactive protein concentration was significantly higher in patients with more extensive disease (P=0·026). Overall, patients with a higher number of diseased vessel had a higher incidence of cardiovascular events during follow-up (chisquared for linear association: 17·90, P for trends <0·0005). This was observed in both men (chi-squared for linear association: 7·27, P for trends=0·007), and women (chi-squared for linear association: 8·20, P for trends 0·004).
Baseline C-reactive protein levels and clinical events during follow-up
Major clinical events observed during follow-up in men and women are shown in Table 6 . Overall, serum C-reactive protein concentration was higher in patients with coronary events compared with those without events (2·60 mg . l 1 [range 1·37-6·20] vs 2·30 mg . l 1 [range 1·04-4·60] respectively, P=0·061). When women on hormone replacement therapy were excluded from analysis, the association between C-reactive protein levels and events reached statistical significance (2·60 mg . l 1 [range 1·34-6·40] vs 2·20 mg . l 1 [range 1·00-4·40] respectively, P=0·046). Patients with events during follow-up were more likely to have a history of prior myocardial infarction than patients without events (P=0·021). These patients also had more extensive coronary artery disease (P<0·001). When variables with a P value <0·20 in the univariate analysis between patients with events and patients without events were introduced into a forward logistic multiple regression analysis, i.e. number of vessels diseased, C-reactive protein levels, age, prior myocardial infarction, gender and left ventricular ejection fraction, only C-reactive protein (log 10 [CRP] odds ratio: 1·68 [1·04-2·72]; P=0·033) and the number of vessels diseased (odds ratio: 1·58 [1·27-1·97]; P<0·0005) were independent predictors of adverse outcome. Gender (P=0·45), prior myocardial infarction (P=0·13), left ventricular ejection fraction (P=0·63) and age (P=0·68) were not independent predictors of events. On repeating the analysis for each of the two genders separately, we observed that vessel disease was an independent predictor of events in both men and women (odds ratio: 1·47 [1·10-1·98]; P=0·008 in men and odds ratio 1·70 [1·17-2·47]; P<0·006 in women). C-reactive protein was an independent predictor of outcome in men (log 10 [CRP] odds ratio: 1·76 [1·01-3·07]; P=0·044) but not in women (P=0·66). In women, hormone replacement therapy was not independently associated with events (P=0·29) despite being independently associated with higher levels of C-reactive protein.
Discussion
The present study aimed to ascertain whether there are baseline C-reactive protein level differences between men and women with chronic stable angina pectoris and also the prognostic implications of baseline C-reactive protein levels in women with coronary artery disease. We did not aim to compare C-reactive protein levels in coronary artery disease patients with normal individuals. We thus included only patients with typical exertional angina and positive responses to exercise stress testing and/or thallium scintigraphy. Our results showed, for the first time, that in consecutive patients with stable exertional chest pain undergoing coronary arteriography, women have higher baseline C-reactive protein levels than men. This difference remained significant after adjustment for confounding variables in a multiple regression model (P=0·001). Although not a direct comparison study of C-reactive protein in men versus women, a report by Ridker et al. [13] on apparently healthy women suggested that C-reactive protein levels were higher in women in their study compared to men Non-HRT women (n=264) Women using HRT (n=63) P
VD=coronary vessel disease (vessels with d75% stenoses); HRT=hormone replacement therapy. There were 89 events in 87 patients (2 patients had both myocardial infarction and stroke).
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previously studied by the same authors. However, in a more recent study these authors observed that men and women had similar baseline C-reactive protein levels [16] . C-reactive protein is an acute-phase reactant produced in the liver, and has a close correlation with fibrinogen, another acute phase reactant [3] . Our findings with C-reactive protein have analogies with previous observations on the role of fibrinogen as a marker of coronary artery disease risk in postmenopausal women [21] [22] [23] [24] , which showed that oestrogen deficient women have higher fibrinogen levels than men, but that the incidence of adverse cardiovascular events was similar in both genders [12] . In our study, despite significantly higher C-reactive protein levels, women had a similar event rate to men during follow-up. Epidemiological and case control studies have also found gender differences in the levels of coronary disease markers such as von Willebrand factor, coagulation factor VIII, antithrombin III, protein C, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator antigen (t-PA) [25] [26] [27] [28] [29] [30] . Haverkate et al. [31] have also reported that antithrombin III antigen and activity, protein C activity, PAI-1 antigen and activity, and t-PA antigen, were all lower in men compared with women >50 years of age. Despite these differences, men and women had a similar incidence of thrombotic events.
C-reactive protein and hormone replacement therapy
In our study, C-reactive protein levels were higher in women receiving hormone replacement therapy than in those not treated with hormone replacement therapy. Both women on hormone replacement therapy and those on no hormone replacement therapy had higher C-reactive protein concentrations than men. Women on hormone replacement therapy were significantly younger, had lower systolic blood pressure, fewer diseased coronary vessels and a better ejection fraction than women who were not on hormone replacement therapy. These findings are in agreement with previous reports indicating that women on hormone replacement therapy have a more favourable coronary artery disease profile than those who do not receive hormone replacement therapy [32] . However, in the present study hormone replacement therapy was independently associated with increased C-reactive protein levels (P=0·001) and this finding is consistent with previous reports in apparently healthy women [15] [16] [17] . This appears to contrast with observational studies showing that increased C-reactive protein levels in women are associated with poor prognosis and with studies showing that hormone replacement therapy may be beneficial regarding cardiovascular risk. However, the HERS study [33] , a randomized study of the effect of hormone replacement therapy on secondary prevention, failed to show any prognostic improvement in coronary artery disease patients receiving hormone replacement therapy. The PEPI study [17] , another prospective double blind randomized study, has shown that women receiving hormone replacement therapy had higher C-reactive protein levels. The authors hypothesized that their finding of increased C-reactive protein may explain the increased cardiovascular event rate detected in the first 2 years of hormone replacement therapy treatment. The reasons for the deleterious effects observed with hormone replacement therapy in women with advanced coronary artery disease are controversial. Whether increased C-reactive protein plays a role is a possibility that deserves careful investigation. In our study, women using hormone replacement therapy had a similar eventrate to women not using hormone replacement therapy, an observation which is consistent with the results of a randomized trial by Hall et al. [34] in which hormone replacement therapy did not have a deleterious effect in women with angina pectoris.
Randomized studies on hormone replacement therapy have shown that this treatment decreases the levels of several molecules involved in the pathogenesis of atherothrombosis, i.e. intercellular adhesion molecule-1 [35] , fibrinogen [36] , factor VII antigen [36] , PAI-1 [37] , and antithrombin [38] . C-reactive protein production by the liver is regulated by cytokines, principally interleukin-6 (IL-6) and tumour necrosis factor (TNF ) [39] . Both IL-6 and TNF have been shown to be modulated by oestrogens [40, 41] . A negative correlation has been found between IL-6 levels and plasma oestradiol [42] , and significantly higher IL-6 levels were observed in postmenopausal women compared with pre-menopausal women [43] . These findings have been confirmed in the experimental setting, as ovariectomy raised IL-6 plasma levels in the mice model [44] . This effect was reversed by hormone replacement therapy [44] . These findings suggest that hormone replacement therapy may increase C-reactive protein through IL-6-and TNF -independent mechanisms.
C-reactive protein and cardiovascular risk
As reported in previous studies [11, 45] , we observed a significant correlation between the number of diseased vessels and patient outcome during follow-up in both men and women. In the group as a whole, patients with higher C-reactive protein concentrations had a significantly higher risk of developing serious cardiac events than patients with lower C-reactive protein levels.
The significantly higher C-reactive protein levels found in a number of large epidemiological studies in patients at high risk of cardiovascular events suggests that C-reactive protein is a marker of cardiovascular risk in the clinical setting. However, most of the studies carried out to date have assessed the prognostic role of C-reactive protein in men only [9, 10] , or included a relatively small proportion of women [7, 8, 11] . Little information is available on the predictive value of C-reactive protein in women [13] , particularly in those with stable angina pectoris. Only 18% (n=17) of the patients included in the study by Liuzzo et al. [7] were women, a proportion comparable to that of the ECAT study, which enrolled 324 women (18%), of whom only 105 had stable angina [11] . Women were well represented in our study (approximately 36%). Our patients were representative of ordinary stable angina patients undergoing coronary angiography and, importantly, the spectrum of coronary artery disease in our study ranged from none to three-vessel disease. Our results confirm previous findings that C-reactive protein is an independent predictor of events during follow-up in patients with typical exertional chest pain. However, the association between C-reactive protein levels and events was less striking in women than in men.
Clinical implications
Despite higher C-reactive protein levels, women in our study had a similar number of coronary events to men, and C-reactive protein levels did not predict outcome in female patients. An explanation for this finding may be a lack of statistical power, as women with events in our study showed a trend towards higher C-reactive protein concentrations than women without events. Because of the longitudinal nature of the study design, and the low event rate observed in patients with chronic stable angina, this study may not have sufficient power to detect a statistically significant association between C-reactive protein and coronary risk in the group of 327 women who had a median follow-up of 1·5 years.
On the basis of the encouraging results of the larger epidemiological and case control studies mentioned above, it is likely that C-reactive protein may be a marker of risk in the clinical setting. However, our results suggest that the transition from the epidemiological findings to the clinical application of C-reactive protein in the individual patient may not be without difficulties. Gender differences exist in baseline C-reactive protein which may need to be taken into account when assessing prognosis based on C-reactive protein levels.
Further studies are required to elucidate the mechanism responsible for the higher C-reactive protein concentration in women compared with men and the effects of hormone replacement therapy on C-reactive protein levels. It is also important to define clinically useful prognostic serum C-reactive protein cut-off values, which may differ in men and women.
